POTUS mentioned the drug crisis last evening. Wanted to share this dig summary:

Ibogaine for treating opiate addiction

Searching old Qresearch posts I found Ibogaine mentioned as an effective anti-addictive compound. All credit to those Anons for their posts.

A review of old and new literature suggests Ibogaine holds great potential to help addicts break their opiate habit. Unfortunately the FDA classification of the natural plant-derived substance as a Schedule 1 (also illegal) drug in 1970 made researching it’s usefulness problematic, so studies have been poorly funded and performed in other countries (where Ibogaine is not illegal).

Since President Donald J. Trump issued a nationwide call to action to address and solve the worst drug crisis in U.S. history, it would seem an appropriate time to use “out of the box” thinking and find ways to include Ibogaine in the therapy options for addicts.

https://www.whitehouse.gov/opioids/

Additional details and links are included below:

From: Brown, TK ; Current Drug Abuse Reviews, 2013, Vol. 6, No. 1

Ibogaine in the treatment of substance dependence.

https://www.ncbi.nlm.nih.gov/pubmed/23627782

INTRODUCTION: BACKGROUND AND HISTORY (abridged)

• Ibogaine’s anti-addictive capabilities were discovered by accident by Lotsof ~ 1963

• Patented for use as anti-addictive by:

Lotsof, Ciba Pharmaceuticals - anti-addictive/ 1950s

Psychiatric use 1950s, 1960s

• 1967: Possession Ibogaine made illegal (? considered an addictive “hallucinogen”)

• 1970: FDA classified Ibogaine a Schedule 1 drug (along with LSD & other psychoactive agents)

Currently unregulated in many countries but illegal in the US, Australia, Belgium, Denmark, France, Sweden, Switzerland.

• 1980’s: Lotsof created Foundation and means to fund animal research into opiate addiction and withdrawal.

• 1989 – 1995: Dutch addict self-help group used Ibogaine to treat a group of addicts and case reports together with animal results the Medication Development Division of the US National Institute of Drug Abuse began supporting preclinical studies and human trials including Dr. Deborah Marsh of University of Miami.

• 1993: Patient in Netherlands died and studies there ended, although an official inquiry found no conclusive evidence of Ibogaine involvement in the death. Dr. March continued her studies however funding ceased related to critical input from “expert” consultants from the Pharmaceutical industry.

1 of 3

>>7079469

Ibogaine continued

EVIDENCE FOR EFFICACY: PRECLINICAL RE-SEARCH, PHARMACOLOGY, AND MECHANISMS OF ACTION

• Lots of details in this section. Summary of older data.

SAFETY

• This is important and likely will be one possible way some “Big Pharma experts” may try to prevent/delay studies: Pre-existing heart-related and other medical conditions were linked to mortality, although possible co-factors were not well established.

ALSO:

• The author states: “Despite its association with the psychedelic counterculture of the 1960’s and its classification as a Schedule I substance in the U.S., there is no evidence to suggest that ibogaine is physiologically or psychologically addictive in animals or in humans, or that it is a substance

with a high potential for abuse [reference]. Aversive side effects such as ataxia and nausea limit the potential for ibogaine’s abuse [reference], as does the often unsettling or disturbing nature of the subjective experience of the drug [references].”

Does this suggest Ibogaine should be removed as a Schedule 1 drug by the FDA so that studies within the USA would be possible? Would Ibogaine be better classified as an “oneiric” substance?

EVIDENCE HUMANS FOR EFFICACY: STUDIES WITH HUMANS

• Older but interesting details.

DISCUSSION

Starting at the end of page 11 through page 14 this is IMHO the most important read. Some excerpts below:

• “The ibogaine medical subculture [reference] continues to grow. Since the beginning open rollment into the current study of12 clinical treatment in Mexico in September of 2010, at least seven ibogaine clinics have operated in Mexico. Two new clinics have opened in Baja California, Mexico within the past nine months (as of July, 2012). Public awareness of ibogaine is expanding too, as more and more stories about ibogaine appear in the popular news media and as the ibogaine subculture’s Internet presence grows. The subculture gained an important measure of legitimacy in July

of 2010 when New Zealand categorized ibogaine as a non-approved prescription medicine.”

• “In sum, the human studies of ibogaine treatment provide some preliminary support for the efficacy of ibogaine in alleviating the considerable discomforts of withdrawal from opiates and other addictive drugs, and thereby in facilitating detoxification from these substances in a comparatively

painless manner…It is possible that research will eventually show that ibogaine is an “addiction interrupter” for many substances of abuse, as Howard Lotsof [reference] and others have insisted.”

2 of 3

>>7079478

Ibogaine continued

Additional info including results from the recent Studies in Mexico that TK Brown referenced as ongoing in his 2013 article. Abstracts posted and links included.

Brown TK, Noller GE, Denenberg JO.

J Psychoactive Drugs. 2019 Apr-Jun;51(2):155-165. 10.1080/02791072.2019.1598603. Epub 2019 Apr 9. https://www.ncbi.nlm.nih.gov/pubmed/30967101

Malcolm BJ1, Polanco M2, Barsuglia JP2.

J Psychoactive Drugs. 2018 Jul-Aug;50(3):256-265. doi: 10.1080/02791072.2018.1447175. Epub 2018 Apr 2.

https://www.ncbi.nlm.nih.gov/pubmed/2960840

Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M.

Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning.

J Psychedelic Stud. 2017 Nov;1(2):65-73. doi: 10.1556/2054.01.2017.009. Epub 2017 Oct 17.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157925/

FDA NOTE:

Found that there is an FDA “Psychopharmacologic Drugs Advisory Committee” but could not find the members listed, or their CVs, and no evidence of recent discussion about Ibogaine.

https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-31-2019-meeting-psychopharmacologic-drugs-advisory-committee-meeting-announcement-07312019

A respectful request:

If any members of this advisory committee are “Anons”, please consider reviewing Ibogaine as a possible treatment option in the future. The recently added anti-addictive sublocade involves dosing monthly by subcutaneous injection in the abdominal region for the first 2 months followed by a maintenance dose of 100 mg monthly. Surely there are better options?

Please don't allow Big Pharma to simply find ways to endlessly profit from this terrible drug crisis.

https://www.pharmacytimes.com/contributor/timothy-o-shea/2018/01/sublocade-for-opioid-use-disorder-what-pharmacists-should-know

http://www.indivior.com/